ES2603352T3 - Anticuerpos neutralizantes contra el receptor de prolactina y su uso terapéutico - Google Patents

Anticuerpos neutralizantes contra el receptor de prolactina y su uso terapéutico Download PDF

Info

Publication number: ES2603352T3
Authority: ES; Spain
Prior art keywords: seq; acid sequence; sequence according; corresponds; amino acid
Prior art date: 2009-12-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES10776753.5T

Other languages

English (en)

Spanish (es)

Inventor

Christiane Otto

Siegmund Wolf

Christoph Freiberg

Axel Harrenga

Simone Greven

Mark Trautwein

Sandra Bruder

Andrea Eicker

Andreas Wilmen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Intellectual Property GmbH

Original Assignee

Bayer Intellectual Property GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-10

Filing date

2010-11-18

Publication date

2017-02-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42091520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2603352(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-11-18 Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH

2017-02-27 Application granted granted Critical

2017-02-27 Publication of ES2603352T3 publication Critical patent/ES2603352T3/es

Status Active legal-status Critical Current

2030-11-18 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Neurology (AREA)
Gynecology & Obstetrics (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Mycology (AREA)
Pregnancy & Childbirth (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

ES10776753.5T 2009-12-10 2010-11-18 Anticuerpos neutralizantes contra el receptor de prolactina y su uso terapéutico Active ES2603352T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09075546A EP2332995A1 (fr)	2009-12-10	2009-12-10	Neutralisation d'anticorps récepteurs de prolactine et leur utilisation thérapeutique
EP09075546		2009-12-10
PCT/EP2010/067747 WO2011069799A1 (fr)	2009-12-10	2010-11-18	Neutralisation des anticorps du recepteur de la prolactine et utilisation therapeutique associee

Publications (1)

Publication Number	Publication Date
ES2603352T3 true ES2603352T3 (es)	2017-02-27

Family

ID=42091520

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES10776753.5T Active ES2603352T3 (es)	2009-12-10	2010-11-18	Anticuerpos neutralizantes contra el receptor de prolactina y su uso terapéutico
ES10782255.3T Active ES2610654T3 (es)	2009-12-10	2010-11-18	Anticuerpos neutralizantes del receptor de prolactina y su uso terapéutico

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES10782255.3T Active ES2610654T3 (es)	2009-12-10	2010-11-18	Anticuerpos neutralizantes del receptor de prolactina y su uso terapéutico

Country Status (40)

Country	Link
US (6)	US20130022606A1 (fr)
EP (13)	EP2332995A1 (fr)
JP (7)	JP6066474B2 (fr)
KR (2)	KR101790366B1 (fr)
CN (6)	CN102741291A (fr)
AP (1)	AP2012006343A0 (fr)
AR (6)	AR079349A1 (fr)
AU (2)	AU2010330161B2 (fr)
BR (2)	BR112012015852B8 (fr)
CA (6)	CA2783678A1 (fr)
CL (2)	CL2012001539A1 (fr)
CR (2)	CR20120310A (fr)
CU (2)	CU20120092A7 (fr)
CY (2)	CY1118209T1 (fr)
DK (2)	DK2510006T3 (fr)
DO (2)	DOP2012000159A (fr)
EA (2)	EA028678B1 (fr)
EC (2)	ECSP12011965A (fr)
ES (2)	ES2603352T3 (fr)
GT (1)	GT201200186A (fr)
HR (2)	HRP20170016T1 (fr)
HU (2)	HUE030143T2 (fr)
IL (2)	IL220151A0 (fr)
IN (2)	IN2012DN05078A (fr)
LT (2)	LT2510002T (fr)
MA (1)	MA33888B1 (fr)
ME (1)	ME02577B (fr)
MX (2)	MX2012006621A (fr)
NZ (2)	NZ600512A (fr)
PE (3)	PE20121561A1 (fr)
PH (2)	PH12012501129A1 (fr)
PL (2)	PL2510006T3 (fr)
PT (2)	PT2510006T (fr)
RS (2)	RS55277B1 (fr)
SG (2)	SG181511A1 (fr)
SI (2)	SI2510002T1 (fr)
TN (1)	TN2012000294A1 (fr)
TW (5)	TW201130506A (fr)
WO (6)	WO2011069796A1 (fr)
ZA (2)	ZA201204213B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2332995A1 (fr) *	2009-12-10	2011-06-15	Bayer Schering Pharma Aktiengesellschaft	Neutralisation d'anticorps récepteurs de prolactine et leur utilisation thérapeutique
PT3345615T (pt)	2010-03-01	2020-01-17	Bayer Healthcare Llc	Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
EP2530089A1 (fr)	2011-06-03	2012-12-05	Bayer Pharma Aktiengesellschaft	Anticorps neutralisant Mat3 contre le récepteur de prolactine et son utilisation thérapeutique
EP2825553B1 (fr)	2012-03-14	2018-07-25	Regeneron Pharmaceuticals, Inc.	Molécules multispécifiques de liaison à des antigènes et leurs utilisations
US8883979B2 (en) *	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
US9592297B2 (en) *	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
CA2896058A1 (fr) *	2012-12-24	2014-07-03	Abbvie Inc.	Proteines de liaison au recepteur de la prolactine et utilisations de celles-ci
TW201513882A (zh)	2013-03-15	2015-04-16	Bayer Healthcare Llc	抗－催乳激素受體抗體調配物
TWI641620B (zh)	2013-08-21	2018-11-21	再生元醫藥公司	抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en)	2013-08-21	2017-01-17	Regeneron Pharmaceuticals, Inc.	Anti-PRLR antibodies and methods for killing PRLR-expressing cells
WO2015168474A1 (fr) *	2014-04-30	2015-11-05	President And Fellows Of Harvard College	Protéines de fusion pour le traitement du cancer et procédés associés
EP3200823B1 (fr)	2014-10-02	2022-11-23	City of Hope	Méditopes multivalents, anticorps de liaison aux méditopes, et leurs utilisations
TWI703156B (zh) *	2015-01-30	2020-09-01	學校法人埼玉醫科大學	抗ａｌｋ２抗體
IL296285A (en)	2015-07-06	2022-11-01	Regeneron Pharma	Multispecific antigen-binding molecules and uses thereof
EP3448891A1 (fr)	2016-04-28	2019-03-06	Regeneron Pharmaceuticals, Inc.	Procédés de production de molécules multispécifiques se liant à l'antigène
EP3548514A1 (fr)	2016-11-29	2019-10-09	Regeneron Pharmaceuticals, Inc.	Méthodes de traitement du cancer du sein positif à prlr
FR3062213B1 (fr) *	2017-01-20	2021-02-26	Endodiag	Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
TW201836647A (zh)	2017-04-06	2018-10-16	美商艾伯維有限公司	抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
US11202776B2 (en) *	2017-05-12	2021-12-21	Takeda Pharmaceutical Company Limited	Treatment of gastroparesis with triazaspiro[4.5]decanone
US20210128728A1 (en)	2017-07-10	2021-05-06	Bayer Pharma Aktiengesellschaft	Prolactin receptor antibody for male and female pattern hair loss
US12258597B2 (en)	2018-02-07	2025-03-25	Regeneron Pharmaceuticals, Inc.	Methods and compositions for therapeutic protein delivery
WO2019169330A1 (fr) *	2018-03-02	2019-09-06	Oncolix, Inc.	Procédé de traitement de cancers exprimant le récepteur de la prolactine
CN109627340B (zh) *	2018-12-05	2021-02-12	上海交通大学	Cd3和prlr双特异性抗体及其构建与应用
US10467487B1 (en) *	2018-12-11	2019-11-05	Chongqing Jinkang New Energy Automobile Co., Ltd.	Fusion-based traffic light recognition for autonomous driving
CN112425568A (zh) *	2020-12-11	2021-03-02	上海市计划生育科学研究所	一种建立具有emt特征的良性前列腺增生bph犬模型的方法
AR124681A1 (es)	2021-01-20	2023-04-26	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
CN114853890B (zh) *	2022-03-16	2023-04-28	沈阳三生制药有限责任公司	一种prlr抗原结合蛋白及其制备方法和应用
CN114634574B (zh) *	2022-04-18	2022-12-20	先进生物(苏州)有限公司	抗B7H6的scFv抗体、其编码基因及其应用
CN118834297A (zh) *	2023-04-24	2024-10-25	深圳真实生物医药科技有限公司	泌乳素受体抗体及其用途
CN117285625B (zh) *	2023-11-24	2024-01-23	南京佰抗生物科技有限公司	抗泌乳素蛋白的单克隆抗体及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4657760A (en)	1979-03-20	1987-04-14	Ortho Pharmaceutical Corporation	Methods and compositions using monoclonal antibody to human T cells
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en)	1985-06-26	1993-04-27	Cetus Oncology Corporation	Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
US4986615A (en)	1988-10-17	1991-01-22	The Vendo Company	Vending apparatus
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5225212A (en)	1989-10-20	1993-07-06	Liposome Technology, Inc.	Microreservoir liposome composition and method
GB9105245D0 (en) *	1991-03-12	1991-04-24	Lynxvale Ltd	Binding molecules
EP0571613B1 (fr)	1991-12-13	2003-09-17	Xoma Corporation	Materiels et methodes pour preparer des domaines variables d'anticorps modifies et leurs utilisations therapeutiques
ES2176484T3 (es)	1995-08-18	2002-12-01	Morphosys Ag	Bancos de proteinas/(poli)peptidos.
US6110471A (en) *	1996-09-13	2000-08-29	The Board Of Trustees Of The Leland Stanford Junior University	Non-hormonal method of contraception
GB9701425D0 (en)	1997-01-24	1997-03-12	Bioinvent Int Ab	A method for in vitro molecular evolution of protein function
US6867187B2 (en) *	2000-12-22	2005-03-15	Trustees Of The University Of Pennsylvania	Composition and method for modulating somatolactogenic function
EP1325930A1 (fr) *	2002-01-08	2003-07-09	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Variants de Prolactin de mammifère
WO2004054516A2 (fr) *	2002-12-13	2004-07-01	The Ohio State University	Antagonistes de la prolactine humaine
GB0305790D0 (en) *	2003-03-13	2003-04-16	Glaxosmithkline Biolog Sa	Novel Composition
JP4954709B2 (ja) *	2004-10-28	2012-06-20	協和発酵キリン株式会社	子宮内膜症治療剤
WO2006089678A2 (fr) *	2005-02-22	2006-08-31	Bioinvent International Ab	Peptides et utilisations de ceux-ci
GB0517878D0 (en) *	2005-09-02	2005-10-12	Bioinvent Int Ab	Immunotherapeutic treatment
US7422899B2 (en)	2005-10-05	2008-09-09	Biogen Idec Ma Inc.	Antibodies to the human prolactin receptor
AR064801A1 (es) *	2006-08-18	2009-04-29	Xoma Technology Ltd	Anticuerpo especifico prlr (receptor de prolactina) y sus usos
CN102711773A (zh)	2007-05-30	2012-10-03	奥克兰联合服务有限公司	生长激素和相关激素的抑制剂,和其使用方法
EP2025683A1 (fr) *	2007-08-13	2009-02-18	INSERM (Institut National de la Santé et de la Recherche Medicale)	Variantes de prolactine servant comme antagonistes de son récepteur
EP2332995A1 (fr) *	2009-12-10	2011-06-15	Bayer Schering Pharma Aktiengesellschaft	Neutralisation d'anticorps récepteurs de prolactine et leur utilisation thérapeutique
WO2011139375A1 (fr) *	2010-05-06	2011-11-10	Ludwig Institute For Cancer Research Ltd	Anticorps dirigés contre l'anhydrase carbonique ix et méthodes et utilisations associées
GB201020995D0 (en) *	2010-12-10	2011-01-26	Bioinvent Int Ab	Biological materials and uses thereof

2009
- 2009-12-10 EP EP09075546A patent/EP2332995A1/fr not_active Withdrawn
2010
- 2010-11-18 US US13/514,995 patent/US20130022606A1/en not_active Abandoned
- 2010-11-18 BR BR112012015852A patent/BR112012015852B8/pt active IP Right Grant
- 2010-11-18 JP JP2012542436A patent/JP6066474B2/ja active Active
- 2010-11-18 HU HUE10782255A patent/HUE030143T2/en unknown
- 2010-11-18 HR HRP20170016TT patent/HRP20170016T1/hr unknown
- 2010-11-18 PH PH1/2012/501129A patent/PH12012501129A1/en unknown
- 2010-11-18 SI SI201031312A patent/SI2510002T1/sl unknown
- 2010-11-18 PL PL10782255T patent/PL2510006T3/pl unknown
- 2010-11-18 EA EA201200860A patent/EA028678B1/ru not_active IP Right Cessation
- 2010-11-18 AU AU2010330161A patent/AU2010330161B2/en active Active
- 2010-11-18 CA CA2783678A patent/CA2783678A1/fr not_active Abandoned
- 2010-11-18 EP EP12192707A patent/EP2570435A1/fr not_active Withdrawn
- 2010-11-18 IN IN5078DEN2012 patent/IN2012DN05078A/en unknown
- 2010-11-18 MX MX2012006621A patent/MX2012006621A/es unknown
- 2010-11-18 HR HRP20161401TT patent/HRP20161401T1/hr unknown
- 2010-11-18 IN IN5082DEN2012 patent/IN2012DN05082A/en unknown
- 2010-11-18 SI SI201031367A patent/SI2510006T1/sl unknown
- 2010-11-18 US US13/514,992 patent/US9649374B2/en active Active
- 2010-11-18 WO PCT/EP2010/067743 patent/WO2011069796A1/fr not_active Ceased
- 2010-11-18 EA EA201200851A patent/EA029327B1/ru not_active IP Right Cessation
- 2010-11-18 CN CN2010800633485A patent/CN102741291A/zh active Pending
- 2010-11-18 DK DK10782255.3T patent/DK2510006T3/en active
- 2010-11-18 NZ NZ600512A patent/NZ600512A/en unknown
- 2010-11-18 KR KR1020127017833A patent/KR101790366B1/ko active Active
- 2010-11-18 PL PL10776753T patent/PL2510002T3/pl unknown
- 2010-11-18 EP EP10781671A patent/EP2510004A1/fr not_active Withdrawn
- 2010-11-18 ES ES10776753.5T patent/ES2603352T3/es active Active
- 2010-11-18 CA CA2783654A patent/CA2783654A1/fr not_active Abandoned
- 2010-11-18 LT LTEP10776753.5T patent/LT2510002T/lt unknown
- 2010-11-18 PE PE2012000797A patent/PE20121561A1/es not_active Application Discontinuation
- 2010-11-18 DK DK10776753.5T patent/DK2510002T3/en active
- 2010-11-18 US US13/514,991 patent/US20120321632A1/en not_active Abandoned
- 2010-11-18 JP JP2012542435A patent/JP2013513364A/ja not_active Ceased
- 2010-11-18 EP EP12192722A patent/EP2567980A1/fr not_active Withdrawn
- 2010-11-18 WO PCT/EP2010/067746 patent/WO2011069798A1/fr not_active Ceased
- 2010-11-18 WO PCT/EP2010/067744 patent/WO2011069797A1/fr not_active Ceased
- 2010-11-18 PE PE2017000782A patent/PE20171134A1/es unknown
- 2010-11-18 EP EP10776753.5A patent/EP2510002B1/fr active Active
- 2010-11-18 MA MA34951A patent/MA33888B1/fr unknown
- 2010-11-18 US US13/514,993 patent/US20130171147A1/en not_active Abandoned
- 2010-11-18 EP EP12192704A patent/EP2567977A1/fr not_active Withdrawn
- 2010-11-18 RS RS20160915A patent/RS55277B1/sr unknown
- 2010-11-18 SG SG2012041166A patent/SG181511A1/en unknown
- 2010-11-18 JP JP2012542434A patent/JP2013513363A/ja active Pending
- 2010-11-18 CA CA2783513A patent/CA2783513C/fr active Active
- 2010-11-18 CA CA2783514A patent/CA2783514A1/fr not_active Abandoned
- 2010-11-18 ES ES10782255.3T patent/ES2610654T3/es active Active
- 2010-11-18 HU HUE10776753A patent/HUE031631T2/en unknown
- 2010-11-18 CN CN2010800634488A patent/CN102858803A/zh active Pending
- 2010-11-18 PH PH1/2012/501131A patent/PH12012501131A1/en unknown
- 2010-11-18 CN CN201080063347.0A patent/CN102947338B/zh active Active
- 2010-11-18 CA CA2783610A patent/CA2783610C/fr active Active
- 2010-11-18 EP EP12192708A patent/EP2567979A1/fr not_active Withdrawn
- 2010-11-18 JP JP2012542433A patent/JP2013513362A/ja active Pending
- 2010-11-18 AU AU2010330165A patent/AU2010330165B2/en active Active
- 2010-11-18 CA CA2783651A patent/CA2783651A1/fr not_active Abandoned
- 2010-11-18 JP JP2012542432A patent/JP2013513361A/ja active Pending
- 2010-11-18 JP JP2012542431A patent/JP2013513559A/ja active Pending
- 2010-11-18 CN CN201080063268XA patent/CN102858801A/zh active Pending
- 2010-11-18 EP EP10781882A patent/EP2510005A1/fr not_active Withdrawn
- 2010-11-18 CN CN2010800634492A patent/CN102858804A/zh active Pending
- 2010-11-18 CN CN201080063269.4A patent/CN102884082B/zh active Active
- 2010-11-18 PT PT107822553T patent/PT2510006T/pt unknown
- 2010-11-18 US US13/514,994 patent/US20120315276A1/en not_active Abandoned
- 2010-11-18 EP EP12192721A patent/EP2570436A1/fr not_active Withdrawn
- 2010-11-18 BR BR112012014048-5A patent/BR112012014048B1/pt active IP Right Grant
- 2010-11-18 KR KR1020127017831A patent/KR101765968B1/ko active Active
- 2010-11-18 EP EP12192705A patent/EP2567978A1/fr not_active Withdrawn
- 2010-11-18 PT PT107767535T patent/PT2510002T/pt unknown
- 2010-11-18 EP EP10782255.3A patent/EP2510006B1/fr active Active
- 2010-11-18 LT LTEP10782255.3T patent/LT2510006T/lt unknown
- 2010-11-18 US US13/514,996 patent/US9241989B2/en active Active
- 2010-11-18 WO PCT/EP2010/067742 patent/WO2011069795A1/fr not_active Ceased
- 2010-11-18 NZ NZ600511A patent/NZ600511A/en unknown
- 2010-11-18 PE PE2012000791A patent/PE20121360A1/es not_active Application Discontinuation
- 2010-11-18 SG SG2012041182A patent/SG181513A1/en unknown
- 2010-11-18 EP EP10784482A patent/EP2510007A1/fr not_active Withdrawn
- 2010-11-18 RS RS20170010A patent/RS55589B1/sr unknown
- 2010-11-18 EP EP10779014A patent/EP2510003A1/fr not_active Withdrawn
- 2010-11-18 AP AP2012006343A patent/AP2012006343A0/xx unknown
- 2010-11-18 WO PCT/EP2010/067747 patent/WO2011069799A1/fr not_active Ceased
- 2010-11-18 MX MX2012006620A patent/MX339343B/es active IP Right Grant
- 2010-11-18 ME MEP-2016-244A patent/ME02577B/fr unknown
- 2010-11-18 WO PCT/EP2010/067740 patent/WO2011069794A1/fr not_active Ceased
- 2010-12-10 TW TW099143330A patent/TW201130506A/zh unknown
- 2010-12-10 AR ARP100104564A patent/AR079349A1/es unknown
- 2010-12-10 AR ARP100104565A patent/AR079350A1/es unknown
- 2010-12-10 TW TW099143326A patent/TW201138817A/zh unknown
- 2010-12-10 AR ARP100104563A patent/AR079348A1/es active IP Right Grant
- 2010-12-10 TW TW099143327A patent/TW201130504A/zh unknown
- 2010-12-10 TW TW099143328A patent/TWI487536B/zh active
- 2010-12-10 TW TW099143332A patent/TWI508744B/zh active
- 2010-12-10 AR ARP100104567A patent/AR079352A1/es active IP Right Grant
- 2010-12-10 AR ARP100104566A patent/AR079351A1/es unknown
- 2010-12-17 AR ARP100104707A patent/AR079641A1/es unknown
2012
- 2012-06-04 IL IL220151A patent/IL220151A0/en active IP Right Grant
- 2012-06-04 IL IL220149A patent/IL220149A/en active IP Right Grant
- 2012-06-07 CU CU2012000092A patent/CU20120092A7/es unknown
- 2012-06-07 CU CU2012000093A patent/CU23973B1/es not_active IP Right Cessation
- 2012-06-08 TN TNP2012000294A patent/TN2012000294A1/en unknown
- 2012-06-08 CL CL2012001539A patent/CL2012001539A1/es unknown
- 2012-06-08 CL CL2012001540A patent/CL2012001540A1/es unknown
- 2012-06-08 EC ECSP12011965 patent/ECSP12011965A/es unknown
- 2012-06-08 DO DO2012000159A patent/DOP2012000159A/es unknown
- 2012-06-08 CR CR20120310A patent/CR20120310A/es unknown
- 2012-06-08 DO DO2012000160A patent/DOP2012000160A/es unknown
- 2012-06-08 GT GT201200186A patent/GT201200186A/es unknown
- 2012-06-08 EC ECSP12011966 patent/ECSP12011966A/es unknown
- 2012-06-08 ZA ZA2012/04213A patent/ZA201204213B/en unknown
- 2012-06-08 CR CR20120312A patent/CR20120312A/es unknown
- 2012-06-08 ZA ZA2012/04214A patent/ZA201204214B/en unknown
2015
- 2015-07-03 JP JP2015134286A patent/JP6199930B2/ja active Active
2016
- 2016-10-31 CY CY20161101101T patent/CY1118209T1/el unknown
2017
- 2017-01-10 CY CY20171100030T patent/CY1118407T1/el unknown

Also Published As

Publication number	Publication date
CN102884082B (zh)	2015-05-20
KR20120112528A (ko)	2012-10-11
SG181511A1 (en)	2012-07-30
US9649374B2 (en)	2017-05-16
DK2510006T3 (en)	2017-01-23
CA2783514A1 (fr)	2011-06-16
CA2783654A1 (fr)	2011-06-16
CA2783513A1 (fr)	2011-06-16
IL220149A0 (en)	2012-07-31
EA029327B1 (ru)	2018-03-30
HK1180354A1 (en)	2013-10-18
CN102858804A (zh)	2013-01-02
PE20121360A1 (es)	2012-10-11
CA2783610C (fr)	2018-10-30
CN102858803A (zh)	2013-01-02
RS55277B1 (sr)	2017-02-28
JP2013513365A (ja)	2013-04-22
JP2013513361A (ja)	2013-04-22
PE20121561A1 (es)	2012-11-25
TW201138817A (en)	2011-11-16
TWI508744B (zh)	2015-11-21
CL2012001539A1 (es)	2012-10-12
EA201200851A1 (ru)	2013-01-30
HUE031631T2 (en)	2017-07-28
BR112012015852B8 (pt)	2021-05-25
CY1118209T1 (el)	2017-06-28
JP6066474B2 (ja)	2017-01-25
LT2510002T (lt)	2016-11-25
ME02577B (fr)	2017-06-20
US20130022606A1 (en)	2013-01-24
ZA201204214B (en)	2014-08-27
CA2783513C (fr)	2018-08-14
PT2510002T (pt)	2016-11-23
AU2010330161B2 (en)	2015-07-09
EP2510005A1 (fr)	2012-10-17
RS55589B1 (sr)	2017-06-30
PH12012501129A1 (en)	2012-11-05
WO2011069795A1 (fr)	2011-06-16
PE20171134A1 (es)	2017-08-09
EP2510006B1 (fr)	2016-11-09
BR112012015852A2 (pt)	2017-05-23
MX2012006620A (es)	2012-06-21
JP6199930B2 (ja)	2017-09-20
IL220149A (en)	2017-09-28
EP2510002B1 (fr)	2016-08-24
EP2567979A1 (fr)	2013-03-13
EP2570435A1 (fr)	2013-03-20
EA201200860A1 (ru)	2013-01-30
AR079349A1 (es)	2012-01-18
EP2510002A1 (fr)	2012-10-17
EP2510007A1 (fr)	2012-10-17
DOP2012000159A (es)	2012-09-30
PH12012501131A1 (en)	2017-08-23
US20130272968A1 (en)	2013-10-17
TN2012000294A1 (en)	2013-12-12
HRP20170016T1 (hr)	2017-02-24
AU2010330165B2 (en)	2015-07-16
EP2567980A1 (fr)	2013-03-13
PL2510006T3 (pl)	2017-06-30
AU2010330161A1 (en)	2012-07-05
JP2013513364A (ja)	2013-04-22
WO2011069796A1 (fr)	2011-06-16
WO2011069795A4 (fr)	2011-08-18
CN102884082A (zh)	2013-01-16
AR079350A1 (es)	2012-01-18
TWI487536B (zh)	2015-06-11
BR112012015852A8 (pt)	2017-06-27
ZA201204213B (en)	2014-08-27
TW201130505A (en)	2011-09-16
CN102741291A (zh)	2012-10-17
CL2012001540A1 (es)	2013-01-18
EP2332995A1 (fr)	2011-06-15
AP2012006343A0 (en)	2012-06-30
CN102858801A (zh)	2013-01-02
SG181513A1 (en)	2012-07-30
AU2010330165A1 (en)	2012-07-19
WO2011069798A1 (fr)	2011-06-16
JP2013513559A (ja)	2013-04-22
WO2011069794A1 (fr)	2011-06-16
TW201130504A (en)	2011-09-16
ECSP12011965A (es)	2012-07-31
EA028678B1 (ru)	2017-12-29
CA2783610A1 (fr)	2011-06-16
KR20120112527A (ko)	2012-10-11
NZ600511A (en)	2014-01-31
BR112012015852B1 (pt)	2020-12-29
AR079348A1 (es)	2012-01-18
PL2510002T3 (pl)	2017-02-28
TW201130507A (en)	2011-09-16
US20120321632A1 (en)	2012-12-20
HUE030143T2 (en)	2017-04-28
MA33888B1 (fr)	2013-01-02
DOP2012000160A (es)	2012-09-30
IN2012DN05078A (fr)	2015-10-23
WO2011069799A1 (fr)	2011-06-16
AR079352A1 (es)	2012-01-18
EP2510003A1 (fr)	2012-10-17
KR101790366B1 (ko)	2017-10-26
JP2015180690A (ja)	2015-10-15
AR079351A1 (es)	2012-01-18
CN102947338B (zh)	2015-11-25
SI2510002T1 (sl)	2016-12-30
CU20120093A7 (es)	2012-10-15
BR112012014048B1 (pt)	2021-10-26
EP2510004A1 (fr)	2012-10-17
CA2783651A1 (fr)	2011-06-16
LT2510006T (lt)	2016-12-12
CR20120312A (es)	2012-08-27
JP2013513362A (ja)	2013-04-22
HRP20161401T1 (hr)	2016-12-16
PT2510006T (pt)	2017-01-20
GT201200186A (es)	2014-01-06
ES2610654T3 (es)	2017-04-28
CU20120092A7 (es)	2012-10-15
CN102947338A (zh)	2013-02-27
ECSP12011966A (es)	2012-07-31
US9241989B2 (en)	2016-01-26
CU23973B1 (es)	2013-12-27
IL220151A0 (en)	2012-07-31
NZ600512A (en)	2014-11-28
WO2011069797A1 (fr)	2011-06-16
IN2012DN05082A (fr)	2015-10-09
US20130129739A1 (en)	2013-05-23
US20120315276A1 (en)	2012-12-13
BR112012014048A2 (pt)	2017-10-31
CY1118407T1 (el)	2017-06-28
CA2783678A1 (fr)	2011-06-16
MX339343B (es)	2016-05-20
EP2567978A1 (fr)	2013-03-13
JP2013513363A (ja)	2013-04-22
DK2510002T3 (en)	2016-11-28
EP2510006A1 (fr)	2012-10-17
EP2567977A1 (fr)	2013-03-13
HK1180700A1 (en)	2013-10-25
AR079641A1 (es)	2012-02-08
TW201130506A (en)	2011-09-16
SI2510006T1 (sl)	2017-02-28
CR20120310A (es)	2012-08-01
MX2012006621A (es)	2012-10-05
KR101765968B1 (ko)	2017-08-08
US20130171147A1 (en)	2013-07-04
EP2570436A1 (fr)	2013-03-20

Publication	Publication Date	Title
ES2603352T3 (es)	2017-02-27	Anticuerpos neutralizantes contra el receptor de prolactina y su uso terapéutico
EP3501536B1 (fr)	2025-12-24	Traitement de maladies oculaires
CN112203695B (zh)	2024-11-01	用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法
CN110392697A (zh)	2019-10-29	对nectin-4具有特异性的抗体及其用途
EP3347054B1 (fr)	2021-05-05	Schéma posologique pour des conjugués médicament-anticorps anti-tf
CN112368020B (zh)	2024-05-31	抗pd-1抗体和抗组织因子抗体-药物偶联物组合治疗癌症的方法
BRPI0608815A2 (pt)	2010-01-26	composições de anticorpo anti-ctla-4
BR112019024620A2 (pt)	2020-06-23	Ligante de proteína nkg2d, cd16 e antígeno associado a tumor
JP2024009998A (ja)	2024-01-23	抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用
CN113260385B (zh)	2025-02-11	抗vegf抗体和抗组织因子抗体-药物偶联物组合治疗癌症的方法
JP2024045219A (ja)	2024-04-02	抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用
MX2013014174A (es)	2014-11-13	El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapeutico.
CA3071817A1 (fr)	2019-02-07	Methodes et compositions pour le traitement des maladies a depots amyloides
CN112739716A (zh)	2021-04-30	使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
CN116322787A (zh)	2023-06-23	抗组织因子抗体-药物偶联物及其在癌症治疗中的用途
CN114650846A (zh)	2022-06-21	用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法
KR20200133233A (ko)	2020-11-26	두부경부암의 치료
CN117159703B (zh)	2024-04-02	含抗lag-3抗体的药物组合物及其用途
MXPA06005540A (es)	2006-08-17	Anticuerpo del receptor anti-igf-i.
HK40045175A (en)	2021-10-15	Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
HK40052936A (en)	2022-01-28	Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
HK40057787B (zh)	2025-08-15	抗vegf抗体和抗组织因子抗体-药物偶联物组合治疗癌症的方法
HK1180700B (en)	2016-04-08	Neutralizing prolactin receptor antibodies and their therapeutic use
NZ623275B2 (en)	2016-08-30	Treatment of ocular disease